Yousuf Razvi
A5072399610- Amyloidosis: Diagnosis, Treatment, Outcomes
- Parathyroid Disorders and Treatments
- Neuroendocrine Tumor Research Advances
- Medical Imaging and Pathology Studies
- Cardiac Imaging and Diagnostics
- COVID-19 Clinical Research Studies
- Eosinophilic Disorders and Syndromes
- Peptidase Inhibition and Analysis
- Cardiomyopathy and Myosin Studies
- Advanced MRI Techniques and Applications
- Sarcoidosis and Beryllium Toxicity Research
- Long-Term Effects of COVID-19
- Lanthanide and Transition Metal Complexes
- Cellular transport and secretion
- Cardiac Arrest and Resuscitation
- Systemic Sclerosis and Related Diseases
- Cardiovascular Effects of Exercise
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Atrial Fibrillation Management and Outcomes
- Trace Elements in Health
- Protein Tyrosine Phosphatases
- Dermatological and Skeletal Disorders
- Skin and Cellular Biology Research
- Cardiovascular Function and Risk Factors
- Functional Brain Connectivity Studies
The Royal Free Hospital
2020-2025
University College London
2020-2025
Royal Free London NHS Foundation Trust
2020-2024
Brigham and Women's Hospital
2024
University of Auckland
2024
Amyloidosis Foundation
2021-2024
BridgeBio (United States)
2024
Children's Cancer and Leukaemia Group
2022
Roland Hill (United Kingdom)
2022
Imperial College Healthcare NHS Trust
2018-2020
Troponin elevation is common in hospitalized COVID-19 patients, but underlying aetiologies are ill-defined. We used multi-parametric cardiovascular magnetic resonance (CMR) to assess myocardial injury recovered patients.One hundred and forty-eight patients (64 ± 12 years, 70% male) with severe infection [all requiring hospital admission, 48 (32%) ventilatory support] troponin discharged from six hospitals underwent convalescent CMR (including adenosine stress perfusion if indicated) at...
Diagnostic and therapeutic advances have led to much greater awareness of transthyretin cardiac amyloidosis (ATTR-CA). We aimed characterize changes in the clinical phenotype patients diagnosed with ATTR-CA over past 20 years. This is a retrospective observational cohort study all referred National Amyloidosis Centre (2002-2021) whom was differential diagnosis. identified 2995 suspected ATTR-CA, 1967 had diagnosis confirmed. Analysis by 5-year periods revealed an incremental increase...
The aim of this study was to characterize left atrial (LA) pathology in explanted hearts with transthyretin amyloid cardiomyopathy (ATTR-CM); LA mechanics using echocardiographic speckle-tracking a large cohort patients ATTR-CM; and the association mortality.The clinical significance involvement ATTR-CM is great interest.Congo red staining immunohistochemistry performed assess presence, type, extent associated changes 5 atria. Echo speckle tracking used reservoir, conduit, contractile...
Abstract Aims To assess the ability of cardiovascular magnetic resonance (CMR) to (i) measure changes in response chemotherapy; (ii) correlation between haematological and extracellular volume (ECV); (iii) association ECV prognosis over above existing predictors. Methods results In total, 176 patients with cardiac AL amyloidosis were assessed using serial N-terminal pro-B-type natriuretic peptide (NT-proBNP), echocardiography, free light chains CMR T1 mapping at diagnosis subsequently 6, 12,...
Abstract Aims The aims of this study were to assess prescription patterns, dosages, discontinuation rates, and association with prognosis conventional heart failure medications in patients transthyretin cardiac amyloidosis (ATTR-CA). Methods results A retrospective analysis all consecutive diagnosed ATTR-CA at the National Amyloidosis Centre between 2000 2022 identified 2371 ATTR-CA. Prescription was greater among a more severe phenotype, comprising beta-blockers 55.4%,...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is often assumed to be associated with wild-type TTR genotype (ATTRwt) in elderly patients (aged ≥70), some of whom are not offered genetic testing. We sought estimate the prevalence, clinical characteristics and prognostic implications transthyretin (TTR) variants among diagnosed ATTR-CM.Data from consecutive over 70 years age ATTR-CM at UK National Amyloidosis Centre between January 2010 August 2022 were retrospectively evaluated. All...
Abstract Aims To perform evaluation of widely embraced bone scintigraphy-based non-biopsy diagnostic criteria (NBDC) for ATTR amyloid cardiomyopathy (ATTR-CM) in clinical practice, and to refine serum free light chain (sFLC) ratio cut-offs that reliably exclude monoclonal gammopathy (MG) chronic kidney disease. Methods results A multi-national retrospective study 3354 patients with suspected or histologically proven cardiac amyloidosis (CA) referred specialist centres from 2015 2021;...
Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive cardiomyopathy. The clinical course varies among individuals and there are no established measures to assess disease progression. goal of this study was the prognostic importance an increase in N-terminal pro–B-type natriuretic peptide (NT-proBNP) outpatient diuretic intensification (ODI) as markers progression large cohort patients with ATTR-CA. We evaluated landmark survival analysis based on worsening NT-proBNP requirement for...
BackgroundTransthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) an investigational therapy based on CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease) targeting the gene encoding transthyretin (TTR).MethodsIn this phase 1, open-label trial, we administered single intravenous infusion of nex-z to patients ATTR-CM. Primary objectives included assessment effect safety...
The 6-minute walk test (6MWT) represents a comprehensive functional assessment that is commonly used in patients with heart failure; however, data are lacking transthyretin cardiac amyloidosis (ATTR-CA).
Cardiac involvement is the main driver of clinical outcomes in systemic amyloidosis and preliminary studies support hypothesis that myocardial ischaemia contributes to cellular damage. The aims this study were assess presence mechanisms using cardiovascular magnetic resonance (CMR) with multiparametric mapping histopathological assessment.
Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive and ultimately fatal cardiomyopathy. Biomarkers reflecting multiorgan dysfunction are of increasing importance in patients with heart failure; however, their significance ATTR-CA remains largely unknown. The aims this study were to characterize the multifaceted nature using blood biomarkers assess association between prognosis. This retrospective cohort 2566 consecutive diagnosed 2007 2023. Anemia (39%), high urea (52%),...
Background Neurofilament light chain (NfL) has emerged as a sensitive biomarker in hereditary transthyretin amyloid polyneuropathy (ATTRv-PN). We hypothesise that NfL can identify conversion of gene carriers to symptomatic disease, and guide treatment approaches.
Importance Patients with transthyretin (ATTR) cardiac amyloid infiltration are increasingly diagnosed at earlier disease stages no heart failure (HF) symptoms and a wide range of infiltration. Objective To characterize the clinical phenotype natural history asymptomatic patients ATTR Design, Setting, Participants This cohort study analyzed data all 12 international centers for amyloidosis from January 1, 2008, through December 31, 2023. Inclusion criteria were infiltration, defined as an...
The prevalence and clinical impact of frailty in transthyretin cardiac amyloidosis (ATTR-CA) remains poorly characterized. This study aimed to evaluate the prevalence, determinants, prognostic significance a large cohort patients with ATTR-CA. Frailty was assessed 880 ATTR-CA (median age 80 years [Q1-Q3: 75-84 years], 719 [81.7%] male) using Clinical Scale (CFS). analyzed as continuous variable categorized CFS 1 3, 4 or 5, 6 7, 8 9. observed 502 (57.1%) (CFS 5: 364 [41.4%]; 7: 129 [14.7%];...
Bone scintigraphy is extremely valuable when assessing patients with suspected cardiac amyloidosis (CA), but the clinical significance and associated phenotype of different degrees uptake across types yet to be defined.This study sought define phenotypes varying on bone scintigraphy, multiple systemic amyloidosis, using extensive characterization comprising biomarkers as well echocardiographic magnetic resonance (CMR) imaging.A total 296 (117 immunoglobulin light-chain [AL], 165...
Systemic light chain amyloidosis is a multisystem disorder that commonly involves the heart, liver, and spleen. Cardiac magnetic resonance with extracellular volume (ECV) mapping provides surrogate measure of myocardial, spleen amyloid burden. The purpose this study was to assess multiorgan response treatment using ECV mapping, association between prognosis. authors identified 351 patients who underwent baseline serum amyloid-P-component (SAP) scintigraphy cardiac at diagnosis, which 171 had...
Cardiac magnetic resonance (CMR) imaging-derived extracellular volume (ECV) mapping, generated from precontrast and postcontrast T1, accurately determines treatment response in cardiac light-chain amyloidosis. Native T1 which can be derived without the need for contrast, has demonstrated accuracy diagnosis prognostication, but it is unclear whether serial native measurements could also track response.To assess mapping measure association between changes prognosis.This single-center cohort...
Cardiopulmonary exercise testing (CPET) has an established role in the assessment of patients with heart failure. However, data are lacking transthyretin (ATTR) amyloidosis.